Profile

Formycon is a globally operating, independent biosimilar specialist with a highly attractive product pipeline and a fully scalable development platform in the fields of ophthalmology, immunology, immuno-oncology and other major indications. With its biosimilars – follow-on products for approved biopharmaceutical drugs – Formycon is making a significant contribution to improving patient access to highly effective and affordable medicines.

Field of activity

Formycon is a "pure-play" biosimilar company. Given its specialized area of focus, the company can cover the entire technical-pharmaceutical development chain, from drug candidate selection, cell line development, comparative analytics, process development and preclinical and clinical development. The team also has extensive expertise in the preparation of approval documents and management of approval procedures in highly reglated markets as well as in establishing and managing all supply chain and product logistics.

Products/Services

In addition to FYB201 (reference product Lucentis®), which has already been approved and launched in key global markets (US, EU, UK, Canada, MENA, etc.), Formycon's development pipeline includes two additional biosimilars as well as four biosimilar candidates with attractive market potential.

The biosimilar FYB202 (reference product Stelara®) is launched in the US, Europe and Canada and approved in the UK. FYB203 (reference product Eylea®) is approved in the US, the EU and the UK. The biosimilar candidate FYB206 for the immuno-oncology blockbuster drug Keytruda® is currently

Formycon. Biosimilar Experts.
Factsheet 2025

Development pipeline



undergoing clinical evaluation. The two undisclosed biosimilar candidates FYB208 and FYB209 are in advanced preclinical development. In addition, the biosimilar development project FYB210 was started in November 2024.

Partnering

Formycon relies on strong, trustworthy and long-term partnerships around the world for the commercialization of its biosimilars:

Biosimilar	Region	Commercialization Partner
FYB201	US	Sandoz AG
	EU	Teva Pharmaceuticals
	MENA	MS Pharma
FYB202	US/EU	Fresenius Kabi
	MENA	MS Pharma
	DE*	Teva Pharmaceuticals
FYB203	EU (major parts)	Teva Pharmaceuticals
	US / Canada	Valorum
	MENA	MS Pharma
	APAC	Lotus Pharmaceutical

*Secondary Commercialization

For the unpartnered biosimilar candidates FYB206, FYB208, FYB209 and FYB210, the project and commercialization rights are held in full by Formycon.

Contact

Sabrina Müller
Director Investor Relations and Corporate Communications
ir@formycon.com

www.formycon.com

About Formycon

Founded: 2012
Sitz: Planegg near Munich
Employees: 250

Management Board

Dr. Stefan Glombitza (CEO)
Nicola Mikulcik (CBO)
Dr. Andreas Seidl (CSO)
Enno Spillner (CFO)

Supervisory Board

Wolfgang Essler (Chairman)
Colin Bond (Deputy Chairman)
Klaus Röhrig (Member)
Nicholas Haggar (Member)
Dr. Bodo Coldewey (Member)

Market data

ISIN: DE000A1EWVY8 · Frankfurt Stock Exchange
Market Segment: Regulated Market (Prime Standard), SDAX, TecDAX
Market Capitalization: ~ € 500 million
Outstanding Shares: 17,664,427

Shareholder Structure



Key financials (according to IFRS in € million)

	2020	2021	2022	2023	2024
Revenue	34.3	36.6	42.5	77.7	69.7
EBITDA	−5.7	−12.4	−15.9	1.5	−13.7
Adjusted EBITDA	--	--	−28.8	13.3	−1.6
Working Capital	44.4	29.5	14.0	38.9	55.1

Formycon News

https://www.formycon.com/en/news-media/press-releases/

2025/07